Publication: Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
Submitted Date
Received Date
Accepted Date
Issued Date
2017-06-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
24058521
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85017120274
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Papillomavirus Research. Vol.3, (2017), 105-115
Citation
Lone K. Petersen, Jaime Restrepo, Edson D. Moreira, Ole Erik Iversen, Punnee Pitisuttithum, Pierre Van Damme, Elmar A. Joura, Sven Erik Olsson, Daron Ferris, Stan Block, Anna R. Giuliano, Xavier Bosch, Sophie Pils, Jack Cuzick, Suzanne M. Garland, Warner Huh, Susanne K. Kjaer, Oliver M. Bautista, Donna Hyatt, Roger Maansson, Erin Moeller, Hong Qi, Christine Roberts, Alain Luxembourg (2017). Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Retrieved from: https://hdl.handle.net/20.500.14594/42786.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
Alternative Title(s)
Author(s)
Lone K. Petersen
Jaime Restrepo
Edson D. Moreira
Ole Erik Iversen
Punnee Pitisuttithum
Pierre Van Damme
Elmar A. Joura
Sven Erik Olsson
Daron Ferris
Stan Block
Anna R. Giuliano
Xavier Bosch
Sophie Pils
Jack Cuzick
Suzanne M. Garland
Warner Huh
Susanne K. Kjaer
Oliver M. Bautista
Donna Hyatt
Roger Maansson
Erin Moeller
Hong Qi
Christine Roberts
Alain Luxembourg
Jaime Restrepo
Edson D. Moreira
Ole Erik Iversen
Punnee Pitisuttithum
Pierre Van Damme
Elmar A. Joura
Sven Erik Olsson
Daron Ferris
Stan Block
Anna R. Giuliano
Xavier Bosch
Sophie Pils
Jack Cuzick
Suzanne M. Garland
Warner Huh
Susanne K. Kjaer
Oliver M. Bautista
Donna Hyatt
Roger Maansson
Erin Moeller
Hong Qi
Christine Roberts
Alain Luxembourg
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Ârhus Universitetshospital
Fundación Centro de Investigación Clínica CIC
Fundacao Oswaldo Cruz
Universitetet i Bergen
Mahidol University
Universiteit Antwerpen
Medizinische Universitat Wien
Karolinska Institutet
Augusta University
Kentucky Pediatric and Adult Research Inc
Moffitt Cancer Center
Institute Catala Oncologia
Barts and The London School of Medicine and Dentistry
Murdoch Children's Research Institute
University of Alabama
Kræftens Bekæmpelse
Merck & Co., Inc.
Fundación Centro de Investigación Clínica CIC
Fundacao Oswaldo Cruz
Universitetet i Bergen
Mahidol University
Universiteit Antwerpen
Medizinische Universitat Wien
Karolinska Institutet
Augusta University
Kentucky Pediatric and Adult Research Inc
Moffitt Cancer Center
Institute Catala Oncologia
Barts and The London School of Medicine and Dentistry
Murdoch Children's Research Institute
University of Alabama
Kræftens Bekæmpelse
Merck & Co., Inc.
Series
Has Part
Abstract
© 2017 The Authors Background The immunogenicity profile of the 9-valent HPV (9vHPV) vaccine was evaluated across five phase III clinical studies conducted in girls and boys 9–15 years of age and young women 16–26 years of age. The effect of baseline characteristics of subjects on vaccine-induced HPV antibody responses was assessed. Methods Immunogenicity data from 11,304 subjects who received ≥1 dose of 9vHPV vaccine in five Phase III studies were analyzed. Vaccine was administered as a 3-dose regimen. HPV antibody titers were assessed 1 month after dose 3 using a competitive Luminex immunoassay and summarized as geometric mean titers (GMTs). Covariates examined were age, gender, race, region of residence, and HPV serostatus and PCR status at day 1. Results GMTs to all 9 vaccine HPV types decreased with age at vaccination initiation, and were otherwise generally similar among the demographic subgroups defined by gender, race and region of residence. For all subgroups defined by race or region of residence, GMTs were higher in girls and boys than in young women. Vaccination of subjects who were seropositive at day 1 to a vaccine HPV type resulted in higher GMTs to that type, compared with those in subjects who were seronegative for that type at day 1. Conclusions 9vHPV vaccine immunogenicity was robust among subjects with differing baseline characteristics. It was generally comparable across subjects of different races and from different regions. Greater immunogenicity in girls and boys versus young women (the population used to establish 9vHPV vaccine efficacy in clinical studies) indicates that the anti-HPV responses generated by the vaccine in adolescents from all races or regions were sufficient to induce high-level protective efficacy. This immunogenicity profile supports a widespread 9vHPV vaccination program and early vaccination.